Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
Where 2seventy bio Stands With Analysts
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 155 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's trading, 103 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
2seventy bio: Q1 Earnings Insights
Via Benzinga
2seventy bio's Return On Capital Employed Overview
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for  
Via Benzinga
Cancer Drug Trials Put On Hold After Patients Died
Recent reports from two drug companies that had been conducing separate clinical trials to evaluate cancer treatments reveal that the trials were halted due to the deaths of six participants, including... 
Via Benzinga
Wedbush Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
Via Benzinga
Where 2seventy bio Stands With Analysts
Via Benzinga
SVB Leerink Maintains Outperform Rating for 2seventy bio: Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2023
Via Benzinga
2seventy Bio Pauses Pediatric Blood Cancer Trial After Patient Death, Stock Plunges
2seventy Bio Inc (NASDAQ: TSVT) announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML), has been paused by Seattle Children's, the company's partner and... 
Via Benzinga
2seventy Bio Stock Crumbles After A Patient Dies In Its Pediatric Cancer Study
The company is investigating whether the death is tied to the experimental drug. 
Via Investor's Business Daily
Expert Ratings for 2seventy bio
Via Benzinga
Week in Review: VectorBuilder Raises $57 Million for Gene Therapy Delivery CDMO
Via Talk Markets
Benzinga Pro's Top 5 Stocks To Watch For Friday, May 12, 2023: CMCSA, KR, ON, TSVT, CMND
Comcast (CMCSA) - The parent company of NBCUniversal. One of Friday's most-discussed stories stemmed from a tweet by Elon Musk he had found a new exec to file the chief exec role at Twitter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 147 stocks made new 52-week lows. 
Via Benzinga
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit
The company could have the best-in-class CAR-T drug for multiple myeloma patients. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Friday
  During Friday's session, 149 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
4 Analysts Have This to Say About 2seventy bio
Over the past 3 months, 4 analysts have published their opinion on 2seventy bio (NASDAQ:TSVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Upgrades 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.